Trials / Completed
CompletedNCT02717858
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | liraglutide | Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached. |
| DRUG | placebo | Injected s.c./subcutaneously (under the skin) once daily. |
Timeline
- Start date
- 2016-03-16
- Primary completion
- 2017-02-27
- Completion
- 2017-02-27
- First posted
- 2016-03-24
- Last updated
- 2018-06-28
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02717858. Inclusion in this directory is not an endorsement.